Abstract This study utilized normal and defective epithelial cell cultures and epidermal skin samples to examine intra- and intercellular calcium signaling. The main interests of this thesis were Hailey-Hailey disease (HHD), Darier disease (DD), neurofibromatosis 1 (NF1) and transitional cell carcinoma (TCC). HHD and DD diseases are rare autosomal dominant skin disorders characterized by dissociation of epidermal keratinocytes (acantholysis) at the suprabasal layer of the epidermis. HHD and DD diseases are caused by mutations in the genes encoding the calcium pumps in the Golgi apparatus (hSPCA1) and endoplasmic reticulum (SERCA2b), respectively. Due to these mutations calcium uptake into the Golgi apparatus or ER is diminished, which is believed to cause abnormal cell junction protein processing and dissociation of keratinocytes. This study utilized electron probe microanalysis (EPMA) and demonstrated for the first time that lesional areas of HHD and DD and non-lesional areas of DD epidermis display abnormally low calcium content in the basal cell layer. Furthermore, ATP mediated calcium signaling was impaired in cultured HHD and DD keratinocytes and epidermal ATP receptor localization was disrupted. In conclusion, these results suggest that the low calcium content in the basal cell layer is the reason for suprabasal ruptures in HHD but not necessarily in DD lesions, and that abnormal ATP receptor localization contributes to the calcium signaling defects. NF1 deficient keratinocytes display abnormally low resting cytosolic calcium levels and it has been suggested that the calcium concentration in the lumen of the endoplasmic reticulum is decreased. This study demonstrated that NF1 keratinocytes rely mostly on ATP mediated calcium signaling while normal keratinocytes rely mostly on gap junctional intercellular communication (GJIC). Studies with TCC cells have demonstrated that gap junctions participate in intercellular calcium wave propagation. This thesis demonstrated that the ATP mediated pathway was also operational in calcium wave propagation in normal uroepithelial and TCC cell cultures. Furthermore, impaired calcium wave propagation in the TCC cell culture could be improved through PKC α/βI –isoenzyme inhibition with Gö6976. Gö6976 treatment increased connexin 26 clustering at plasma membrane but did not alter expression level of the protein. This thesis contains a wide repertoire of calcium detection techniques including a new cutting-edge technology for elemental calcium detection of epidermal samples. These techniques can be used for molecular specific analysis of calcium signaling in epithelial cells.

The aim of the study was to evaluate the importance of brain MRI's findings, and modify the criteria for brain MR imaging in NF1 patients according to this data, to improve the quality of life with early detection of important NF1 complications. Description of the whole cohort, with emphasise to possible cause of high range of sporadic NF1 cases. Evaluation the possibility diagnosis or follow up of brain gliomas by plasmatic values of neuron specific enolase (NSE) and S100B protein. Subjects and methods: I analysed data from 285 NF1 children followed up on our department from 1990 to 2010 by the same examination battery. I evaluated the incidence of brain MRI findings, clinical development, age at gliomas manifestation and necessity of treatment. I also described the whole cohort and made statistic analysis of plasmatic values of NSE and S100B protein in NF1 patients, with and without brain gliomas. Results: OPGs were found in 77/285 (27 %) children and GOOPs in 29/285 (10.2 %) of NF1 children, of who 19 had OPG and GOOP together, so the total number of brain glioma was 87/285 (30.5 %). Totally, 43/87 (49.4 %), respectively 43/285 (15.1 %) children with brain glioma were treated, and 4/285 (1.4 %) of this children died. Obstructive hydrocephalus was found in 22/285 (7.7 %) patients and was caused...

Indiana University-Purdue University Indianapolis (IUPUI) / Neurofibromatosis type 1 is a genetic disease that results from either heritable or spontaneous autosomal dominant mutations in the NF1 gene, which encodes a protein serving, at least in part, to accelerate the intrinsic hydrolysis of active Ras-GTP to inactive Ras-GDP. A second-hit NF1 mutation precedes predominant NF1 neoplasms, including juvenile myelomoncytic leukemia (JMML) and plexiform neurofibroma formation, potentially fatal conditions with no medical therapy. While NF1 loss of heterozygosity (LOH) in myeloid progenitor cells sufficiently engenders leukemogenesis, plexiform neurofibroma formation depends on LOH in Schwann cells and Nf1 heterozygosity in the hematopoietic system. Specifically, recruited Nf1+/- mast cells accelerate tumorigenesis through secreted cytokines and growth factors. Nf1+/- mast cells depend upon deregulated signaling in c-kit pathways, a receptor system conserved in hematopoietic stem cells (HSCs). Accordingly, Nf1-/- myeloid progenitor cells, which can induce a JMML-like disease in mice, also demonstrate deregulated c-kit receptor signaling. C-kit-activated Nf1+/- mast cells and Nf1-/- myeloid progenitors both show increased latency and potency of active Erk1 and Erk2, the principal cytosolic-to-nuclear effectors of canonical Ras-Raf-Mek signaling. Thus, Erk represents a potential regulator of leukemogenesis and tumor-associated inflammation. However, single and combined Erk1 and Erk2 roles in HSC function, myelopoiesis, and mature mast cell physiology remain unknown, and recent hematopoietic studies relying on chemical Mek-Erk inhibitors have produced conflicting results. Here, we show that hematopoietic stability, myelopoiesis, and mast cell generation require Erk1 or Erk2, but individual isoforms are largely dispensable. Principally, Erk-disrupted hematopoietic stem cells incorporate BrdU but are incapable of dividing, a novel and cell type-specific Erk function. Similarly, mast cell proliferation requires Erk but cytokine production proceeds through other pathways, elucidating molecule-specific functions within the c-kit cascade. Based on these findings, we have reduced tumor mast cell infiltration by treating genetically-engineered tumor model mice with PD0325901, a preclinical Mek-Erk inhibitor. Moreover, we have devised a quadruple transgenic HSC transplantation model to examine dual Erk disruption in the context of Nf1 nullizygosity, testing whether diseased hematopoiesis requires Erk. These insights illuminate cell-specific Erk functions in normal and Nf1-deficient hematopoiesis, informing the feasibility of targeting Mek-Erk in NF1-associated disease.

NF1 ist eine autosomal dominante Erbkrankheit, die durch inaktivierende Mutationen im Neurofibromin-Gen verursacht wird. NF1 manifestiert sich durch eine erhöhte Tumor-Inzidenz des neuralen Gewebes in der Haut (Neurofibroma). Neben diesen häufigeren klinischen Manifestationen haben rund 50% der NF1-Patienten Skelett-Anomalien. Häufiger sind Röhrenknochen betroffen, die klinischen Symptome reichen von Tibia-Krümmung über Spontanfrakturen bis hin zu Nonunions. Diese Studie analysiert den Heilungsverlauf von Femurfrakturen in Nf1Prx1- Mäusen. Der Frakturkallus von Mäusen wurde an den Tagen 7, 10, 14 und 21 durch µCT, Histologie und molekulare Analysen evaluiert. µCT und histologische Analysen haben eine beeinträchtigte Knochenheilung in Nf1Prx1-Mäusen gezeigt. Eine erhöhte periostale Knochenbildung in den frühen Stadien der Heilung war zu beobachten, sowie eine reduzierte, aber anhaltende Knorpelbildung und Bindegewebs-Akkumulation innerhalb der Fraktur. Wir konnten zeigen, dass der normalen Heilungsprozess durch dieses Bindegewebe behindert wird, welches durch alpha smooth muscle actin-positive Myofibroblasten gebildet wird, die ihrerseits aus einer bisher noch nicht identifizierten Muskelfaszie abgeleitet sind. Dieser Zusammenhang wird durch eine Microarray-Analyse der Kallus-Gewebe bestätigt, die ergab, dass durch den Knock-Out Gene reguliert wurden, die in Physiologie, Proliferation und Differenzierung von Muskelzellen involviert sind. Darüber hinaus waren extrazelluläre-Matrix-Gene in den Mutanten hoch regeuliert. Zusammenfassend konnten wir zeigen, dass eine Ähnlichkeit des Heilungsverlauf zwischen dem Nf1Prx1-Mausmodell und NF1-Patienten besteht. Folglich kann an diesem Mausmodell untersucht werden, durch welche Mechanismen die Mutationen im NF1 zu Knochenheilungsstörungen führen. Außerdem konnte in einer Pilotstudie der Effekt des Neurofibromin-Mangels auf die Knochenheilung durch Behandlung mit MEK-Inhibitoren in vitro und in vivo weitestgehend behoben werden / Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease resulting from inactivating mutations in the gene encoding the protein neurofibromin. NF1 patients – around 50% – have abnormalities of the skeleton. Long bones are often affected, and the clinical signs range from tibial bowing to spontaneous fractures and even non-unions. Moreover, NF1 mice models could provide the understanding of the cell types involved in the resulting non-union and their behavior. This study analyzed the healing progress of femur fractures in a model of NF1 long bone dysplasia. Fracture callus was assessed at days 7, 10, 14, and 21 by µCT, histology, biomechanics, and molecular analyses. Bone healing was impaired in Nf1Prx1 mice femoral fracture. Results revealed increased periosteal bone deposition at the early stages of healing, decreased but persistent cartilage formation concomitant with fibrous tissue accumulation within the fracture site, decreased torsional stiffness, decreased bone mineral density, and increased fibrous tissue infiltration in the callus of mutant mice. This fibrous tissue accumulation hindered bone fracture healing, and was deposited by alpha smooth muscle actin-positive myofibroblasts, which were derived from a yet unidentified muscle fascia. This is further supported by the microarray analysis of callus tissues showing that genes crucial to muscle cells physiology, proliferation and differentiation were affected. In addition, extracellular matrix related genes were up-regulated in the mutants. In summary, this study shows a resemblance in the healing progression to the Nf1Prx1 mice model and NF1 patients, thereby, confirming the suitability of this mice model to explore the mechanism by which mutations in NF1 lead to non-unions. Moreover, in vitro and in vivo pilot assessments of MEK inhibitor treatment demonstrated a potential remedy for the lack of neurofibromin in bone healing.

No description available.

Made available in DSpace on 2016-01-26T12:51:31Z (GMT). No. of bitstreams: 1 joserobertolopesferrazfilho_tese.pdf: 1409103 bytes, checksum: de6715f2f3059b0c5617f571b89bfdbd (MD5) Previous issue date: 2011-10-21 / Neurofibromatosis type 1 (NF1) in children and adolescents is frequently associated with the appearance of focal lesion hyperintensities on T2-weighted images seen in the brain which are called Unidentified Bright Objects (UBOs). These lesions are not an accepted criterion in the diagnosis of NF1 and the exact nature of UBOs remains unclear. Objectives: article 1: This study employed diffusion tensor imaging (DTI) to evaluate the relation among fractional anisotropy (FA) patterns with the findings of T2 sequences in individuals with NF1; article 2: To evaluate the evolution of UBOs in individuals with NF1 by serial MRI, and to relate this to regional fractional anisotropy (FA); article 3: To evaluate the metabolic patterns by magnetic resonance spectroscopy (MRS) of the brain, in the presence of UBOS in patients with NF1. Methods: article 1: Forty-four individuals with NF1 and 20 control subjects were evaluated. The comparative analysis of FA between NF1 and control groups was based on four pre-determined anatomic regions of the brain and related to the presence or absence of UBOs; article 2: The signal pattern of the T2-weighted sequences in the basal ganglia, thalamus, brain stem, and cerebellum for 27 NF1 individuals and a control group were analyzed by DTI. The presence or absence of UBOs in 2 consecutive MRI examinations were related to FA. article 3: Forty-two individuals with NF1 and 25 control subjects were evaluated by examination of ERM univoxel placed in the region of the globus pallidus. Automated quantitative analysis was made of the relationship of the metabolites choline/creatine (Co / Cr), N-acetyl aspartate/creatine (NAA / Cr) and myoinositol/creatine (MI / Cr) and related to the occurrence of UBOS in region of the globus pallidus. Results: article 1: The FA values between the groups demonstrated statistically significant differences (p &#8804; 0.05) for the cerebellum and thalamus in NF1 patients, independent of the occurrence of UBOs; article 2: We demonstrated statistically significant differences in FA for the basal ganglia, cerebellum, and thalamus between NF1 patients and controls (P &#8804; 0.05), even with a reduction or disappearance of UBOs; article 3: We demonstrated statistically significant differences between of patients with NF1 and control groups as the average values Mi/Cr and Co/Cr (P<0.05) in the region of the globus pallidus. Conclusions: article 1: MR imaging using DTI technique suggests that UBOs are due to microstructural defect of the brain tissue in NF1 patients. article 2: MRI allows for adequate monitoring of the temporal and spatial distribution of UBOs in patients with NF1. DTI confirmed changes in FA despite the disappearance or reduction of UBOs. article 3: MR spectroscopy allows the characterization of the tissue abnormalities not demonstrable in the conventional MR sequences of patients with NF1 by analysis of metabolites Co and Mi. / A neurofibromatose tipo 1 (NF1) em crianças e adolescentes está frequentemente associada com o aparecimento ou desaparecimento de lesões focais de hipersinal no encéfalo na ponderação T2 (FHE-T2). Estas lesões não são aceitas como critério diagnóstico para NF1 e sua natureza exata ainda não está clara. Objetivos: artigo 1: Avaliar a relação entre a presença dos FHE-T2 e padrões de anisotropia fracionada (FA) em uma série de pacientes com NF1; artigo 2: Demonstrar o padrão de evolução dos FHE-T2 por exame de Ressonância Magnética (RM) em indivíduos com NF1 e relacionar com o valor regional de FA; artigo 3: Avaliar os padrões metabólicos por meio da espectroscopia por ressonância magnética (ERM) do encéfalo na presença dos FHE-T2 em pacientes com NF1. Métodos: artigo 1: Analisou-se uma série de 44 indivíduos com NF1, e 20 controles. A análise quantitativa do FA foi definida em quatro regiões anatômicas pré-determinadas e relacionada à presença de FHE-T2; artigo 2: Analisou-se com imagem de tensor de difusão (DTI) a evolução dos FHE-T2 nas regiões de núcleos da base, tálamos, cerebelo e tronco encefalico de um grupo de 27 pacientes com NF1 e 20 controles. A presença de FHE-T2 em dois exames de RM encefálica consecutivos foram relacionados com o valor de FA; artigo 3: Analisou-se 42 indivíduos com NF1, e 25 controles saudáveis por exame de ERM univoxel na região do globo pálido. Foi feita análise automatizada quantitativa da relação dos metabólitos colina/creatina (Co/Cr), N-acetil aspartato/creatina (Naa/Cr) e Mioinositol/creatina (Mi/Cr) e relacionada à ocorrência de FHE-T2 na região do globo pálido. Resultados: artigo 1: Os FHE-T2 foram diagnosticados em 50% dos pacientes com NF1. Observou-se redução do valor de FA nas regiões do cerebelo e tálamo de aparência normal ou com FHE-T2 de pacientes com NF1 em relação ao controle (P &#8804;.05); artigo 2: Houve redução significativa no valor de FA nas regiões de núcleos da base, cerebelo e tálamos em pacientes com NF1 em relação ao grupo controle (P &#8804;.05) mesmo com redução ou desaparecimento dos FHE-T2; artigo 3: Houve diferença estatisticamente significante entre os grupos de pacientes com NF1 e o controle quanto aos valores médios ( ) de Mi/Cr e Co/Cr (P<0,05) na região do globo pálido. Conclusões: artigo 1: A técnica de DTI confirma que os FHE-T2 estejam relacionados às alterações da microestrutura do tecido cerebral em pacientes NF1. artigo 2: A RM possibilita o adequado monitoramento da distribuição no tempo e espaço dos FHE-T2 em pacientes com NF1. DTI evidencia alterações no valor de FA mesmo com o desaparecimento ou redução dos FHE-T2; artigo 3: A ERM permite a caracterização de anormalidades teciduais não demonstráveis nas sequências convencionais de RM de pacientes com NF1 por meio da análise dos metabólitos Co e Mi.

Os gliomas de vias ópticas (GVO) representam 5% dos tumores cerebrais pediátricos e geralmente aparecem histologicamente como astrocitomas de baixo grau. Por causa do curso imprevisto dos GVO, as opções de tratamento ainda são controversas, envolvendo vigilância, cirurgia, quimioterapia e radioterapia. Neste estudo, realizamos a análise volumétricas de gliomas de vias ópticas envolvendo as regiões óptico-quiasmáticas e hipotalâmica (GOQH) para comparar a evolução as neoplasias tratadas com e sem quimioterapia, comparando o volume e componentes das lesões. Foram analisados retrospectivamente 14 pacientes com (GOQH) que foram submetidos a Ressonância Magnética em nosso departamento de janeiro de 2000 a outubro de 2015. Um total de 45 RM de encéfalo foram incluídas, com uma média de 3,2 estudos/paciente. A avaliação das lesões foi realizada manualmente por um Neurorradiologista, usando o Software DISPLAY. Quatro destes pacientes eram portadores de NF-1. Oito foram tratados com quimioterapia, sendo carboplatina e vincristina (Carbo/VCR) os agentes de primeira linha. As medidas volumétricas foram realizadas com separação entre os componentes sólidos e císticos das neoplasia, usando as sequências FLAIR e T1 pós contraste, com o apoio de imagens ponderadas em T1 e T2. Um aumento de aproximadamente 30% do volume para as lesões sólidas e uma redução de 19,4% no volume das lesões sólido-císticas foram observados no período global após o tratamento com quimioterapia, porém ambos sem significância estatística. Entre os pacientes não tratados, observou-se uma redução de 16,6 % do volume global das lesões durante o período de acompanhamento. A avaliação da eficácia do tratamento para pacientes com GOQH é difícil, dada a raridade de casos e heterogeneidade radiológica. Os dados de algumas publicações argumentam que o valor da quimioterapia é controverso e não se correlaciona com a resposta radiológica. Em nosso estudo observamos uma pequena redução do volume de neoplasias entre os pacientes tratados e não tratados com quimioterapia, porém sem significância estatística. Ensaios clínicos prospectivos são necessários para melhor avaliar o efeito da quimioterapia sobre OPG. / Optic pathway gliomas (OPG) represent 5% of pediatric brain tumors and generally appear histologically as low-grade astrocytomas. Because of the unpredictable course of OPG, adequate treatment method has been controversial, involving surveillance, surgery, chemotherapy and radiotherapy. In this study, we use volumetric imaging to compare evolution between OPG treated with and without chemotherapy, analyzing the volume and components of the lesions. We retrospectively analyzed 14 patients with OPG who underwent MRI in our department from January 2000 to October 2015. A total of 45 brain MRI were included, with an average of 3,2 studies/patient. The assessment of lesions was manually performed by a neuroradiologist, using software DISPLAY. Four of these patients had NF-1. Eight were treated with chemotherapy, using carboplatin and vincristine (Carbo/VCR) as first-line agents. Volumetric measurements of tumors were segmented into solid and cystic components using FLAIR and T1 weighted images after Gadolinium sequences, with support of T1 and T2 weighted images. An increase of approximately 30% of volume for solid lesions and a decrease of 19,4% for solid-cystic lesions were noted following chemotherapy in overall period, both with no statistical significance. Among patients not treated with chemotherapy, we observed a reduction of 16% in overall volume of the lesions Evaluation of treatment efficacy for OPG patients is difficult, given the rarity of cases and radiological heterogeneity. Data from some publications argued that the value of chemotherapy is controversial and does not correlate with radiological response. From our study we observed a small volume reduction of neoplasms among patients treated and not treated with chemotherapy. Larger prospective clinical trials are needed to better evaluate the effect of chemotherapy on OPG.

Os gliomas de vias ópticas (GVO) representam 5% dos tumores cerebrais pediátricos e geralmente aparecem histologicamente como astrocitomas de baixo grau. Por causa do curso imprevisto dos GVO, as opções de tratamento ainda são controversas, envolvendo vigilância, cirurgia, quimioterapia e radioterapia. Neste estudo, realizamos a análise volumétricas de gliomas de vias ópticas envolvendo as regiões óptico-quiasmáticas e hipotalâmica (GOQH) para comparar a evolução as neoplasias tratadas com e sem quimioterapia, comparando o volume e componentes das lesões. Foram analisados retrospectivamente 14 pacientes com (GOQH) que foram submetidos a Ressonância Magnética em nosso departamento de janeiro de 2000 a outubro de 2015. Um total de 45 RM de encéfalo foram incluídas, com uma média de 3,2 estudos/paciente. A avaliação das lesões foi realizada manualmente por um Neurorradiologista, usando o Software DISPLAY. Quatro destes pacientes eram portadores de NF-1. Oito foram tratados com quimioterapia, sendo carboplatina e vincristina (Carbo/VCR) os agentes de primeira linha. As medidas volumétricas foram realizadas com separação entre os componentes sólidos e císticos das neoplasia, usando as sequências FLAIR e T1 pós contraste, com o apoio de imagens ponderadas em T1 e T2. Um aumento de aproximadamente 30% do volume para as lesões sólidas e uma redução de 19,4% no volume das lesões sólido-císticas foram observados no período global após o tratamento com quimioterapia, porém ambos sem significância estatística. Entre os pacientes não tratados, observou-se uma redução de 16,6 % do volume global das lesões durante o período de acompanhamento. A avaliação da eficácia do tratamento para pacientes com GOQH é difícil, dada a raridade de casos e heterogeneidade radiológica. Os dados de algumas publicações argumentam que o valor da quimioterapia é controverso e não se correlaciona com a resposta radiológica. Em nosso estudo observamos uma pequena redução do volume de neoplasias entre os pacientes tratados e não tratados com quimioterapia, porém sem significância estatística. Ensaios clínicos prospectivos são necessários para melhor avaliar o efeito da quimioterapia sobre OPG. / Optic pathway gliomas (OPG) represent 5% of pediatric brain tumors and generally appear histologically as low-grade astrocytomas. Because of the unpredictable course of OPG, adequate treatment method has been controversial, involving surveillance, surgery, chemotherapy and radiotherapy. In this study, we use volumetric imaging to compare evolution between OPG treated with and without chemotherapy, analyzing the volume and components of the lesions. We retrospectively analyzed 14 patients with OPG who underwent MRI in our department from January 2000 to October 2015. A total of 45 brain MRI were included, with an average of 3,2 studies/patient. The assessment of lesions was manually performed by a neuroradiologist, using software DISPLAY. Four of these patients had NF-1. Eight were treated with chemotherapy, using carboplatin and vincristine (Carbo/VCR) as first-line agents. Volumetric measurements of tumors were segmented into solid and cystic components using FLAIR and T1 weighted images after Gadolinium sequences, with support of T1 and T2 weighted images. An increase of approximately 30% of volume for solid lesions and a decrease of 19,4% for solid-cystic lesions were noted following chemotherapy in overall period, both with no statistical significance. Among patients not treated with chemotherapy, we observed a reduction of 16% in overall volume of the lesions Evaluation of treatment efficacy for OPG patients is difficult, given the rarity of cases and radiological heterogeneity. Data from some publications argued that the value of chemotherapy is controversial and does not correlate with radiological response. From our study we observed a small volume reduction of neoplasms among patients treated and not treated with chemotherapy. Larger prospective clinical trials are needed to better evaluate the effect of chemotherapy on OPG.

Neurofibromatosis Type 1 (NF1) is a monogenetic autosomal-dominant disorder with a broad spectrum of clinical symptoms and is commonly associated with cognitive deficits. Patients with NF1 frequently exhibit cognitive impairments like attention problems, working memory deficits and dysfunctional inhibitory control. The latter is also relevant for the resolution of cognitive conflicts. However, it is unclear how conflict monitoring processes are modulated in NF1. To examine this question in more detail, we used a system neurophysiological approach combining high-density ERP recordings with source localisation analyses in juvenile patients with NF1 and controls during a flanker task. Behaviourally, patients with NF1 perform significantly slower than controls. Specifically on trials with incompatible flanker-target pairings, however, the patients with NF1 made significantly fewer errors than healthy controls. Yet, importantly, this overall successful conflict resolution was reached via two different routes in the two groups. The healthy controls seem to arrive at a successful conflict monitoring performance through a developing conflict recognition via the N2 accompanied by a selectively enhanced N450 activation in the case of perceived flanker-target conflicts. The presumed dopamine deficiency in the patients with NF1 seems to result in a reduced ability to process conflicts via the N2. However, NF1 patients show an increased N450 irrespective of cognitive conflict. Activation differences in the orbitofrontal cortex (BA11) and anterior cingulate cortex (BA24) underlie these modulations. Taken together, juvenile patients with NF1 and juvenile healthy controls seem to accomplish conflict monitoring via two different cognitive neurophysiological pathways.

Neurofibromatosis Type 1 (NF1) is a monogenetic autosomal-dominant disorder with a broad spectrum of clinical symptoms and is commonly associated with cognitive deficits. Patients with NF1 frequently exhibit cognitive impairments like attention problems, working memory deficits and dysfunctional inhibitory control. The latter is also relevant for the resolution of cognitive conflicts. However, it is unclear how conflict monitoring processes are modulated in NF1. To examine this question in more detail, we used a system neurophysiological approach combining high-density ERP recordings with source localisation analyses in juvenile patients with NF1 and controls during a flanker task. Behaviourally, patients with NF1 perform significantly slower than controls. Specifically on trials with incompatible flanker-target pairings, however, the patients with NF1 made significantly fewer errors than healthy controls. Yet, importantly, this overall successful conflict resolution was reached via two different routes in the two groups. The healthy controls seem to arrive at a successful conflict monitoring performance through a developing conflict recognition via the N2 accompanied by a selectively enhanced N450 activation in the case of perceived flanker-target conflicts. The presumed dopamine deficiency in the patients with NF1 seems to result in a reduced ability to process conflicts via the N2. However, NF1 patients show an increased N450 irrespective of cognitive conflict. Activation differences in the orbitofrontal cortex (BA11) and anterior cingulate cortex (BA24) underlie these modulations. Taken together, juvenile patients with NF1 and juvenile healthy controls seem to accomplish conflict monitoring via two different cognitive neurophysiological pathways.